Гипергомоцистеинемия и диабетическая нефропатия: влияние генетических факторов, клинико-патогенетические взаимосвязи с воспалением и анемией

Автор: Пчелин И.Ю., Гапешин Р.А., Худякова Н.В., Байрашева В.К.

Журнал: Juvenis scientia @jscientia

Рубрика: Медицинские науки

Статья в выпуске: 6, 2016 года.

Бесплатный доступ

В работе рассмотрены патогенетические факторы и клиническое значение гипергомоцистеинемии при диабетической нефропатии. Суммированы данные о влиянии полиморфизма гена метилентетрагидрофолатредуктазы на развитие и прогрессирование поражения почек при сахарном диабете. Проанализированы взаимосвязи гипергомоцистеинемии с провоспалительными цитокинами и анемией при диабетической нефропатии. Сформулированы направления дальнейших клинических исследований.

Гомоцистеин, метилентетрагидрофолатредуктаза, сахарный диабет, хроническая болезнь почек, диабетическая нефропатия, анемия, воспаление, полиморфизм

Короткий адрес: https://readera.ru/14110236

IDR: 14110236

Список литературы Гипергомоцистеинемия и диабетическая нефропатия: влияние генетических факторов, клинико-патогенетические взаимосвязи с воспалением и анемией

  • Демидова Т. Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля//Сахарный диабет. 2010. № 3. С. 111-116.
  • Шестакова М. В., Шамхалова М. Ш., Ярек-Мартынова И. Я. и соавт. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения//Сахарный диабет. 2011. № 1. С. 81-88.
  • Худякова Н.В., Пчелин И.Ю., Шишкин А.Н., Иванов Н.В., Василькова О.Н. Гипергомоцистеинемия и кардиоренальный анемический синдром при сахарном диабете//Нефрология. 2015. Т. 19. №6. С. 20-27.
  • Cabarcapa V., Deric M., Stosic Z. et al. Determining the relationship between homocysteinemia and biomarkers of inflammation, oxidative stress and functional kidney status in patients with diabetic nephropathy//J. Med. Biochem. 2013. Vol. 32. P. 131-139.
  • Mudd S.H., Levy H.L., Kraus J. Disorders of Transsulfuration. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., Childs B., Kinzler K., Vogelstein B., eds. The metabolic and molecular bases of inherited diseases//Mc Grow Hill. 2001. P. 2007-2056.
  • Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk//J. Appl. Genet. 2008. Vol. 49. № 3. P. 267-282.
  • Cacciapuotu F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties//J. Thromb. Thrombolysis. 2011. Vol. 32. P. 82-88.
  • Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases//Arch. Med. Sci. 2012. Vol. 8. № 1. P. 138-153.
  • Araki A., Hosoi T., Orimo H., Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes//Metabolism Clinical and Experimental. 2005. Vol. 54. P. 809-814.
  • Gojo Tomic N., Marusic S., Bozikov V. et al. The Relationship between Methylenetetrahydrofolate Reductase C677T Gene Polymorphism and Diabetic Nephropathy in Croatian Type 2 Diabetic Patients//Coll. Antropol. 2013. Vol. 37. № 3. P. 789-793.
  • Chwatko G., Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans//Clin. Chem. 2005. Vol. 51. P. 408-415.
  • Yeh Y.-C., Huang M.-F., Hwang S.-J. et al. Association of homocysteine level and vascular burden and cognitive function in middle-aged and older adults with chronic kidney disease//Int. J. Geriatr. Psychiatry. 2015. Vol. 31. P. 723-730.
  • Kontoangelos K., Papageorgiou C., Raptis A. et al. Homocysteine, Cortisol, Diabetes Mellitus, and Psychopathology//J. Diabetes Res. 2015. P. 1-10.
  • Ndrepepa G., Kastrati A., Braun S. et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus//Nutrition, Metabolism and Cardiovascular Diseases. 2008. Vol. 18. P. 66-73.
  • Wang H., Cui K., Xu K., Xu S. Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients//Int. J. Clin. Exp. Med. 2015. Vol. 8. № 7. P. 11174-11180.
  • Wollesen F., Brattstrom L., Refsum H. et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus//Kidney Int. 1999. Vol. 55. P. 1028-1035.
  • Mtiraoui N., Ezzidi I., Chaieb M. et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients//Diabetes Research and Clinical Practice. 2007. Vol. 75. P. 99-106.
  • Liew S.-C., Gupta E.D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases//European Journal of Medical Genetics. 2015. Vol. 58. P. 1-10.
  • Monsalve M.V., Salzano F.M., Rupert J.L. et al. Methylenetetrahydrofolate Reductase (MTHFR) Allele Frequencies in Amerindians//Annals of Human Genetics. 2003. Vol. 67. P. 367-371.
  • Ukinc K., Ersoz H.O., Karahan C. et al. Methylentetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy//Endocrine. 2009. Vol. 36. P. 255-261.
  • Zhou T.-B., Drummen G., Jiang Z.-P. et al. Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and diabetic nephropathy susceptibility in patients with type 2 diabetes mellitus//Renal Failure. 2015. Vol. 37. № 8. P. 1247-1259.
  • Brattstrom L., WiIcken D., Ohrvik J. et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis//Circulation. 1998. Vol. 98. P. 2520-2526.
  • Eldibany M.M., Caprini J.A. Hyperhomocysteinemia and thrombosis: an overview//Arch. Pathol. Lab. Med. 2007. Vol. 131. P. 872-884.
  • Zintzaras E., Uhlig K., Koukoulis G. et al. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis//J. Hum. Genet. 2007. Vol. 52. P. 881-890.
  • Soares A., Fernandes A., Cardoso J. et al. Plasma Total Homocysteine Levels and Methylenetetrahydrofolate Reductase Gene Polymorphism in Patients with Type 2 Diabetes Mellitus//Pathophysiol. Haemost. Thromb. 2009. Vol. 36. P. 275-281.
  • Boger C., Stubanus M., Haak T. et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy//Nephrol. Dial. Transplant. 2007. Vol. 22. P. 154-162.
  • Zsom M., Fulop T., Zsom L. et al. Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients//Hemodialysis International. 2011. Vol. 15. P. 501-508.
  • Hasegawa G., Obayashi H., Kamiuci K. et al. The Association Between End-Stage Diabetic Nephropathy and Methylenetetrahydrofolate Reductase Genotype with Macroangiopathy in Type 2 Diabetes Mellitus//Exp. Clin. Endocrinol. Diabetes. 2003. Vol. 111. P. 132-138.
  • El-Baz R., Settin A., Ismaeel A. et al. MTHFR C677T, A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients//Journal of Renin-Angiotensin-Aldosterone system. 2012. Vol. 13. № 4. P. 472-477.
  • Sun J., Xu Y., Zhu Y., Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients//Diabetes Research and Clinical Practice. 2004. Vol. 64. P. 185-190.
  • Ksiazek P., Bednarek-Skublewska A., Buraczynska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus//Med. Sci. Monit. 2004. Vol. 10. № 2. P. 47-51.
  • Rahimi M., Hasanvand A., Rahimi Z. et al. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro-and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus//Clinical Biochemistry. 2010. Vol. 43. P. 1333-1339.
  • Nemr R., Salman R., Jawad L. et al. Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs//Clin. Chem. Lab. Med. 2010. Vol. 48. № 8. P. 1091-1094.
  • El Hajj Chehadeh S., Jelinek H., Al Mahmeed W. et al. Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of type 2 diabetes mellitus in an Emirati population//Meta Gene. 2016. Vol. 9. P. 70-75.
  • Jafari Y., Rahimi Z., Vaisi-Raygani A. et al. Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients//Mol. Cell. Biochem. 2011. Vol. 353. P. 23-34.
  • Movva S., Alluri R., Venkatasubramanian S. et al. Association of Methylene Tetrahydrofolate Reductase C677T Genotype With Type 2 Diabetes Mellitus Patients With and Without Renal Complications//Genetic Testing and Molecular Biomarkers. 2011. Vol. 15. № 4. P. 257-261.
  • Eroglu Z., Erdogan M., Tetik A. et al. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy//Diabetes Metab. Res. Rev. 2007. Vol. 23. P. 621-624.
  • Maeda M., Yamamoto I., Fukuda M. et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients//Journal of Diabetes and Its Complications. 2008. Vol. 22. P. 119-125.
  • Baggott J.E, Tamura T. Homocysteine, iron and cardiovascular disease: a hypothesis//Nutrients. 2015. Vol. 7. P. 1108-1118.
  • Makhro A., Wang J., Vogel J. et al. Functional NMDA receptors in rat erythrocytes//Am. J. Physiol. Cell Physiol. 2010. Vol. 298. P. C1315-C1325.
  • Acharya U., Gau J. T., Horvath W. et al. Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature//J. Hematol. Oncol. 2008. Vol. 1. P. 26.
  • Пчелин И.Ю., Шишкин А.Н., Худякова Н.В., Василькова О.Н. Патогенетические факторы и клинические особенности анемии у пациентов с ранними стадиями диабетической нефропатии//Научный аспект. 2015. № 3. C. 258-270.
Еще
Статья научная